Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1671 participants.
Also called NCT02699645
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,671 participants
- Registry
-
NCT02699645
-
- Other papers using this trial's data
- Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Brazil, Georgia, Malaysia, Netherlands, Nigeria, Singapore, Sri Lanka, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02699645. Randomized; quadruple masking; primary purpose prevention. Start 2017-09-28 (actual); primary completion 2025-08-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial
- Acronym
- TRIDENT
- Condition
- Intracerebral Haemorrhage (ICH)
- Condition
- Hypertension
- Intervention (Drug)
- telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- The George Institute
- Collaborator
- The University of New South Wales
Record details
- Record id
cardio:ct-nct02699645- Content hash
506dc0d1c58581d857867ed4e4d167f81b6518c3eb6d20de9c9625ce53ee4bef